Elekta leads radiation therapy industry through innovation

ATLANTA, US, September 23 – Elekta’s strategy to be number one in the radiation
therapy industry is built on developing advanced products, software and
services, which will continue to drive strong growth, according to President and
CEO, Tomas Puusepp. He spoke today at the Elekta Capital Markets Day in Atlanta,
Georgia during the 55th Annual Meeting of the American Society for Radiation
Oncology (ASTRO).
“Elekta’s 40-year history is built upon innovation,” he told the audience of
analysts and investors. “And we continue to create history every day by
inventing new, revolutionary products and solutions that effectively treat
cancer and improve the lives of patients.” He said that Elekta is investing more
in research and development than ever before, to improve patient care around the
world.

Members of Elekta’s executive management presented several novel products and
solutions at the Capital Markets Day, including Versa HD™, Elekta’s new flagship
linear accelerator (linac). Dee Mathieson, Senior Vice President, Oncology
Business Line Management explained how sales of Versa HD, which allows an
unprecedented combination of High Dose Rate delivery and rapid MLC leaf speed,
have exceeded expectations. It has been shipped to 13 countries since its launch
in March. She also introduced Elekta’s new X-ray Volume Imaging (XVI) system
that enables real-time X-ray monitoring of internal motion during radiotherapy
delivery.

John Lapré, Executive Vice President, Elekta Brachytherapy said the launch of
Esteya®, an elegant new approach to high-precision skin cancer treatment using
electronic brachytherapy, was further proof of Elekta’s commitment to
innovation. Other examples included development of the MR linac project, a
solution that combines radiotherapy delivery and simultaneous magnetic resonance
imaging (MRI); and how Elekta continues to drive the stereotactic radiosurgery
(SRS) market with Leksell Gamma Knife®. Todd Powell, Executive Vice President,
Elekta Software, presented Monaco 5.0, the latest evolution of treatment
planning software.

The Elekta Learning and Innovation Center (LINC) is another proof point of
Elekta’s dedication to bringing better treatment to more people. LINC is
designed to mirror a cancer center and will be a role model for Elekta’s global
education and training program.

Renowned professors confirmed Elekta’s leading role as a pioneer and partner in
cancer care. Professor Frederik Wenz, Director of the Department of Radiation
Oncology of the University Medical Center Mannheim, Germany spoke about Elekta’s
latest treatment possibilities. Dr. Dheerendra Prasad, Professor of Neurosurgery
and Radiation Oncology, at Roswell Park Cancer Institute, Buffalo, New York
recounted his 20 years experience of treating patients using Leksell Gamma
Knife® Perfexion™.

Versa HD™ is not available for sale in all markets. Esteya® and Monaco 5.0 are
pending 510(k) clearance.

# # #

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, e-mail: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 15:00 CET on September 23, 2013.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.